Considering GLP-1 medications like semaglutide? Learn how Eden connects you with independent licensed providers for guidance on your weight-related health goals.
Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, was initially approved by the FDA for the treatment of type 2 diabetes under the brand name Ozempic®. Subsequently, it received approval for chronic weight management as Wegovy® .
While some healthcare providers prescribe semaglutide off-label to support metabolic health and weight-related goals, access should always begin with medical oversight.
If you're considering semaglutide for weight loss, this guide outlines the steps, clinical qualifications, and how telehealth platforms like Eden can connect you with licensed providers for care that may include GLP-1-based therapies when appropriate.
Semaglutide is a type of GLP-1 receptor agonist, a class of medications used under medical supervision for managing certain health conditions. One FDA-approved form of semaglutide, marketed as Wegovy®, is approved for chronic weight management in adults with obesity or overweight and at least one weight-related condition.
In clinical trials, including the STEP 1 study, adults with obesity or overweight who were prescribed semaglutide (Wegovy®) alongside dietary and lifestyle support experienced an average weight reduction of up to 14.9% over 68 weeks.
Note: This data applies specifically to the FDA-approved medication Wegovy® and may not reflect results from other versions or uses of semaglutide. Always consult a licensed provider to determine whether a GLP-1-based treatment is appropriate for your individual health needs.
Prescription medications in the GLP-1 class, such as semaglutide, must be evaluated and prescribed by a licensed healthcare provider. Eligibility is determined based on clinical guidelines and an individual’s overall health profile.
A provider may consider GLP-1 treatment for adults who meet one of the following criteria:
In addition to BMI, providers typically assess the following during the consultation:
Treatment decisions are made on a case-by-case basis by the prescribing provider. Eden’s role is to help you connect with licensed clinicians who can guide you through the process when eligible.
Access to GLP-1 medications like semaglutide begins with a clinical evaluation by a licensed provider. Eden offers a telehealth platform that connects patients with qualified medical professionals who can assess eligibility and discuss treatment options based on individual needs.
Schedule a virtual consultation through Eden’s secure telehealth platform. During this visit, a licensed clinician will learn more about your health goals and determine whether GLP-1-based care may be appropriate.
Share your medical history, current medications, and lifestyle habits through a secure intake process. Your provider may also request lab work to help determine whether treatment is appropriate.
Based on your health information and clinical guidelines, the provider will determine if a prescription is appropriate. If eligible, your provider may discuss options that include FDA-approved GLP-1 medications.
If prescribed, your treatment plan may include a gradual dose schedule designed to support tolerability and safety. Your provider will give clear instructions on how to begin and adjust as needed.
Follow-up visits are an important part of care. Providers may check in regularly to assess your progress, adjust your treatment plan, and offer support with lifestyle changes that complement your medical care.
Whether you're exploring care in person or through a telehealth platform, licensed medical providers are the only professionals who can evaluate your eligibility for GLP-1 medications like semaglutide.
Visiting a clinic or healthcare office may provide immediate access to physical exams and on-site lab testing. Some patients prefer the familiarity and face-to-face interaction of traditional care settings.
Eden offers a digital platform that connects you with licensed healthcare providers from the comfort of your home. Through secure virtual visits, providers can evaluate your medical history, order lab work when needed, and determine whether treatment—including GLP-1 medications—is clinically appropriate.
Note: All prescribing decisions are made solely by independent, licensed providers. Eden does not practice medicine or dispense medications.
The out-of-pocket cost of GLP-1 medications, such as semaglutide, can vary significantly depending on the brand, insurance coverage, and pharmacy pricing. Approved options like Wegovy® and Ozempic® may retail for $800–$950 per month without insurance.
Depending on your provider’s recommendation and your individual insurance plan, you may have access to:
Your provider can help you understand which medications may be clinically appropriate and guide you on navigating coverage or affordability options.
Note: Eden does not prescribe or dispense medication. If treatment is prescribed, medications are filled by licensed third-party pharmacies.
Exploring GLP-1 medications like semaglutide for weight-related goals starts with connecting to the right medical provider. Whether you're just beginning your research or ready to take the next step, Eden offers a trusted telehealth platform that helps you connect with licensed clinicians for personalized, judgment-free care.
If appropriate, a provider may prescribe FDA-approved GLP-1 medications as part of a comprehensive treatment plan that supports your long-term health goals.
Eden does not practice medicine or dispense medications. Eden’s role is to connect individuals with independent, licensed providers. If a provider determines that treatment is appropriate, medications are filled by state-licensed third-party pharmacies.
This content is intended for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Any decision to begin a prescription medication must be made by a licensed healthcare provider based on an individual’s unique health profile.
Semaglutide is approved by the U.S. Food and Drug Administration (FDA) under the brand name Ozempic® for the treatment of type 2 diabetes and under the brand name Wegovy® for chronic weight management in adults with obesity or those who are overweight with at least one weight-related condition.
All prescribing decisions are made solely by licensed medical providers. Treatment plans are based on clinical guidelines, medical history, and a provider’s professional judgment.
Disclaimer: The FDA does not approve compounded medications for safety, quality, or manufacturing. Prescriptions and a medical evaluation are required for certain products. The information provided on this blog is for general informational purposes only. It is not intended as a substitute for professional advice from a qualified healthcare professional and should not be relied upon as personal health advice. The information contained in this blog is not meant to diagnose, treat, cure, or prevent any disease. Readers are advised to consult with a qualified healthcare professional for any medical concerns, including side effects. Use of this blog's information is at your own risk. The blog owner is not responsible for any adverse effects or consequences resulting from the use of any suggestions or information provided in this blog.
